DNMT3A Co‐Mutation and Real‐World Clinical Outcomes With Gilteritinib in FLT3‐Mutated Acute Myeloid Leukaemia Across Molecular Subgroups
Francesca Duca, Beatrice Manghisi, Andrea Palasciano, Anna Mochi, Matteo Parma, Rosa Greco, Roberto Cairoli, Carlo Gambacorti‐Passerini, Monica FumagalliABSTRACT
Introduction:
Molecular co‐mutations modulate outcomes in FLT3 ‐mutated AML treated with gilteritinib; real‐world data stratified by DNMT3A co‐mutation status are lacking.
Methods
We retrospectively analysed 29 adults with R/R FLT3 ‐mutated AML treated at two Italian centres. Sixteen patients with complete molecular profiling were stratified into three subgroups by DNMT3A and NPM1 co‐mutation status.
Results
Overall response rate was 89.7% (26/29). DNMT3A ‐mutated subgroups showed prolonged OS from gilteritinib initiation versus wild‐type group (median not reached vs. 8.8 months; 12‐month OS 78% vs. 17%).
Conclusions
These hypothesis‐generating data suggest that DNMT3A co‐mutation status is associated with differential gilteritinib outcomes, supporting comprehensive molecular profiling in FLT3 ‐mutated AML.
Trial Registration
The authors have confirmed clinical trial registration is not needed for this submission